Genzyme in Geel
Genzyme’s state-of-the-art cell culture production facility for therapeutic proteins in Geel is among the largest bio-manufacturing sites in Europe.
The facility is designed as a multi-product facility for suspension and continuous mammalian cell culture production. The suspension cell culture capacity includes two 10,000L stirred tank bioreactors, the accompanying seed bioreactors, medium/buffer preparation tanks and purification train. The perfusion cell culture capacity includes two 4000L bioreactors, with seed train and dedicated purification train. A third 4000L bioreactor is currently in validation. Genzyme in Geel has fully equipped quality control laboratories housed within a 4,000 m2 office/laboratory building.
Two of Genzyme’s main therapies will be manufactured in the Geel facility:
 | A monoclonal antibody for the treatment of B-cell chronic lymphocytic leukemia. The approval for its manufacturing for the EU and the US was received in 2009 and 2010. The treatment is also being evaluated in a number of clinical trials for treatment of other cancers and multiple sclerosis.
|
| An enzyme therapy product for the treatment of Pompe disease, a rare but often fatal genetic muscle disorder. The product was approved in 2006 for treatment in Europe and the US. The first regulatory approval for commercial production of this product in Geel was achieved on February 25th, 2009. In the meanwhile further regulatory approval for commercial production of this enzyme was received for other areas: Japan, Canada, US and Brazil. |
The implementation of the Genzyme manufacturing plant is expected to significantly increase Genzyme’s overall global capacity and help meet the continually increasing demand for its innovative products.
Our work environment
|
Last year Genzyme’s Geel facility was listed among the top 10 “Best Places to Work” in Belgium, ranking eight among companies with less than 500 employees. The Great Place to Work Survey captures the appreciation of the employees for their company. This is the site's fourth consecutive top-10 selection (after 2004, 2006, and 2008). The strong values and satisfaction of our employees have been constant success factors throughout this transformation. The current number of employees is 450.
|
We offer:
| One of the largest state-of-the-art biopharmaceutical manufacturing facilities within continental Europe
|
| Broad technical capabilities and experience in biopharmaceutical development and manufacturing
|
| Extensive learning and development opportunities
|
| A positive work environment in which individuals and teams can excel and are valued |
A unique culture that nourishes:
| Rich social interaction and teamwork (variety of informal teambuilding events...)
|
| An employee-friendly working environment (work-life balance, mother-child friendly company, on-site cafeteria...)
|
| A strong focus on community relations
|
| Celebration and recognition initiatives |
|
|
|
Genzyme Belgium Home
